Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06951503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 3
SponsorAkeso
Started2025-05-27
View on ClinicalTrials.gov ↗

Amendment history

2026-03-03
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05-09→confirmed 2025-05-27
Study sitesdetails revised at 2 of 2 sites
Study title-62 characters
A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
2025-04-23
Original filing
Akeso
96 trials monitored
See 1 trial at risk
Colorectal Cancer
2,904 trials monitored
See 127 trials at risk
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Trial Details
NCT Number NCT06951503
Lead Sponsor Akeso
Conditions Colorectal Adenocarcinoma
Enrollment 560 participants
Start Date 2025-05-27
Primary Completion 2027-01-13 (estimated)
Study Completion 2029-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-04